Vaxcyte Reports Positive Data From Phase 1/2 Study Of Pneumococcal Conjugate Vaccine Candidate
(RTTNews) - Vaxcyte, Inc. (PCVX) Tuesday reported positive topline data from the Phase 1/2 study evaluating VAX-31, the Company's 31-valent pneumococcal conjugate vaccine (PCV) candidate to prevent invasive pneumococcal disease (IPD), in adults aged 50 and older.
In the Phase 1/2 study, VAX-31 was observed to be well tolerated and showed a safety profile at all doses studied through the full six-month evaluation period. Further, VAX-31 showed robust opsonophagocytic activity (OPA) immune responses for all 31 serotypes at all doses studied.
The company plans to initiate a Phase 3 study of VAX-31 by mid-2025 and announce topline data in 2026.
Vaxcyte also plans to initiate VAX-31 infant Phase 2 Study in the first quarter of 2025.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.